Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Montirelin

Next Previous
Drug Profile

Montirelin

Alternative Names: CG 3703; CNK 602A; NS 3; Remnos

Latest Information Update: 31 May 2001

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grunenthal
  • Developer Grunenthal; Nippon Shinyaku
  • Class Antidepressants; Antiepileptic drugs; Hormones; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Thyrotropin-releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cognition disorders; Epilepsy

Most Recent Events

  • 31 May 2001 Discontinued-II for Cognition disorders in Germany (Unknown route)
  • 31 May 2001 Discontinued-preregistration for Cognition disorders in Japan (Unknown route)
  • 31 May 2001 Discontinued-Unspecified phase in Epilepsy in Japan (Unknown route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top